FDA receives reports of two deaths tied to counterfeit retatrutide
The same endocrinology roundup notes Novo Nordisk will discontinue liraglutide (Saxenda) in early 2027 and Zealand's petrelintide cut weight up to 9.2%.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 13 15:32 ETSource: MedPage Today
The wire
- 01Two deaths linked to counterfeit versions of the investigational triple agonist retatrutide were reported to the FDA, alongside lawsuits alleging severe adverse events from GLP-1 receptor agonists.
- 02Gray-market retatrutide is widely sold as a research chemical, so clinicians and telehealth operators face patients sourcing an unapproved molecule with no quality control.
- 03Other items: WHO advises against weight-loss drugs under age 10, oral semaglutide topped 100,000 new prescriptions in two months, and Saxenda is being withdrawn on declining sales.
From the source
Read at medpagetoday.comBootleg Retatrutide Deaths? PMOS and Dementia; Weight-Loss Drug to Be Discontinued
— News and commentary from the endocrinology world
